骨关节炎的单克隆抗体治疗.

BACKGROUND: Studies have shown that a large amount of inflammatory factors produce in the occurrence of osteoarthritis, and antibodies against inflammatory factors have recently become a research hotspot. OBJECTIVE: To summarize the latest research progress of monoclonal antibodies for the treatment of osteoarthritis, and to provide references for the clinical treatment of osteoarthritis. METHODS: A computer search of CNKI, WanFang, PubMed and Web of Science databases was conducted for relevant articles published from January 2006 to May 2020. The key words were “osteoarthritis; monoclonal antibody; inflammatory factors.” After consulting related articles, a total of 69 articles were finally included for result analysis. RESULTS AND CONCLUSION: Osteoarthritis is an inflammatory and degenerative disease. Compared with traditional non-steroidal anti-inflammatory drugs, monoclonal antibodies have shown good effects in the treatment of osteoarthritis pain due to their good targeting and low side effects. Some monoclonal antibodies will increase the risk of joint replacement in patients, so the choice of drugs should vary from person to person. As research continues to deepen, more monoclonal antibodies against different targets will be produced, providing more options for clinical treatment of osteoarthritis. [ABSTRACT FROM AUTHOR]